“Scemblix is the first CML treatment to show significantly better ... with sales last year rising nearly 180% to $413 million from its second-line use and, according to GlobalData, approval ...

Millions of individuals rely on effective medications to manage diseases like cancer and diabetes. For those with chronic myeloid leukemia (CML), advancements in treatment selection could ...

First-in-class STAMP inhibitor Scemblix (asciminib) is already starting to see sales ramp up as a third-line or later therapy for CML – an indication approved by the FDA in 2021 – with a third ...

Officials are taking steps to ensure minimal traffic disruptions as they prepare for the construction of a new Denver soccer ...

The results of this study support the role for this drug as first-line therapy for CML. Nilotinib is more selective at inhibiting BCR-ABL than any other protein tyrosine kinases, and the ...